Pacira BioSciences Inc (PCRX) Actualités

Pacira Announces 104-Week Safety and Efficacy Data Following Local Administration of PCRX-201 for Moderate to Severe Osteoarthritis of the Knee

PARSIPPANY, N.J., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX), the industry...

Pacira BioSciences to Participate in Fireside Chat at Two Upcoming Healthcare Conferences

PARSIPPANY, N.J., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Pacira BioSciences Reports Third Quarter 2024 Financial Results

-- Conference call today at 4:30 p.m. ET -- PARSIPPANY, N.J., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Pacira...

Form 4 - Statement of changes in beneficial ownership of securities

Centers for Medicare and Medicaid Services (CMS) Establishes Additional Payment for iovera in Outpatient Settings

-- Final CMS rule concludes iovera is a qualifying device for separate payment under the NOPAIN Act...

Pacira to Report Third Quarter 2024 Financial Results on Wednesday November 6, 2024

PARSIPPANY, N.J., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX) today announced...

Form 3 - Initial statement of beneficial ownership of securities

Form 8-K - Current report

Pacira BioSciences Appoints Shawn Cross as Chief Financial Officer

TAMPA, Fla., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader...

Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

TAMPA, Fla., Oct. 07, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader...

Pacira BioSciences Announces New Product-Specific J-Code for EXPAREL Effective January 1, 2025

-- New J-code issued by the Centers for Medicare and Medicaid Services expected to standardize and streamline...

Form 8-K - Current report

Pacira Announces the Presentation of 104-Week Safety and Efficacy Data Following Local Administration of PCRX-201 for Moderate to Severe Osteoarthritis of the Knee

-- Poster to be presented at ACR Convergence annual meeting -- TAMPA, Fla., Sept. 26, 2024 (GLOBE NEWSWIRE...